This is a nutritional test that provides insights into the body’s cellular metabolic processes. It identifies metabolic blocks that can be treated nutritionally, and allows individual tailoring of interventions that maximize patient responses and leads to improved patient outcomes. Using a single urine specimen this test is valuable for determining:

• Functional vitamin status, including B-vitamin need
• Neurotransmitter metabolites
• Mitochondrial energy production
• Methylation sufficiency
• Markers for digestion, and small intestinal bacterial and yeast overgrowth

Fatty acid imbalances can be a causative factor in a variety of chronic health conditions, including chronic pain/inflammatory conditions, depression, cardiovascular, aging and neurological diseases. This blood test measures levels of polyunsaturated 3 and 6 fatty acids, trans fats, saturated fats, and fatty-acid ratios. Dietary and nutraceutical intervention can be used to correct imbalances.

This is an advanced stool test that provides immediate, actionable clinical information for the management of gut health. Using the most innovative technologies available, this ground-breaking stool test offers:

• PCR (Polymerase Chain Reaction), a molecular assay optimized for stool testing which assesses 24 commensal bacteria associated in the scientific literature with health and disease, and provides valuable insight into the human microbiome.
• Calprotectin, a biomarker that effectively differentiates between Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), such as Crohn’s and Ulcerative Colitis. Additional inflammatory markers measured, Secretory IgA and Eosinophil Protein X.
• Culture of beneficial and potentially pathologic bacteria, along with antibiotic and botanical sensitivities, where indicated.
• Ova & Parasite, the gold standard for parasite detection.
• Markers for digestion of protein and fats.
• Levels of short chain fatty acids shown to exert multiple beneficial effects on energy metabolism.
• Levels of beta glucuronidase which correlate with the risk of colorectal cancer.
• Stool (and serum) Zonulin, a protein modulator of intestinal tight junctions that is used to assess intestinal permeability (“Leaky Gut”).

Increases in blood-brain barrier proteins (IgG + IgA combined, and IgM) are associated with a wide variety of neuro-inflammatory conditions.

The State University of New York (SUNY) Stony Brook Lyme Disease Laboratory, established in 1984, has gained recognition in the diagnosis of Lyme disease as being one of the select laboratories where accurate laboratory testing for Lyme disease can be obtained. This reputation has resulted in a large number of specimens being received worldwide for testing. Despite this large volume, the laboratory takes pride in providing a high level of technical expertise and personal care to its clients. The laboratory is fully licensed and accredited by the NY State Department of Health, JCAHO, and the College of American Pathologists. We believe that the use of this laboratory provides the highest degree of confidence in the accuracy of the diagnosis of Lyme disease. Testing includes Lyme serology (ELISA/Screening), Lyme Western Blot (Confirmatory), Lyme C-6 peptide (ELISA/Screening), and tick identification. C-6 peptide testing has been reported to have 75, 85, and 100% sensitivity with the acute, convalescent, and late-phase specimens, respectively, and a specificity of 99%.

Using a practitioner-exclusive platform, PureGenomics, we can identify the common genetic variations known as Single Nucleotide Polymorphisms (SNPs) that are clinically relevant and nutritionally actionable. This unique platform makes it easy to test, translate, and target SNPs with the right nutritional support.